secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001213900-21-056585
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics reports Q3 2021 net loss of $10.8M; FDA clears IND for TARA-002 in NMIBC
--------------------------------------------------------------------------------

- Net loss $10.8M ($0.96/sh) vs $8.0M ($1.26/sh) in Q3 2020; R&D expense $4.1M (up from $2.8M), G&A $6.7M (up from $5.3M).
- Cash, equivalents and marketable debt securities $138.4M as of Sept 30, 2021.
- FDA cleared IND for TARA-002 in non-muscle invasive bladder cancer; Phase 1 trial start planned by year-end 2021.
- Hired Mary Grendell (ex-Intercept Pharmaceuticals) as General Counsel; completed GMP comparability for TARA-002.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021056585/0001213900-21-056585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021056585/ea149909-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-056585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer